191 related articles for article (PubMed ID: 8363402)
21. A distinct profile of serum levels of soluble intercellular adhesion molecule-1 and intercellular adhesion molecule-3 in mycosis fungoides and Sézary syndrome.
López-Lerma I; Estrach MT
J Am Acad Dermatol; 2009 Aug; 61(2):263-70. PubMed ID: 19615537
[TBL] [Abstract][Full Text] [Related]
22. Erythrodermic cutaneous T cell lymphoma with hypereosinophilic syndrome: Treatment with interferon alfa and extracorporeal photopheresis.
Lee CH; Mamelak AJ; Vonderheid EC
Int J Dermatol; 2007 Nov; 46(11):1198-204. PubMed ID: 17988344
[TBL] [Abstract][Full Text] [Related]
23. Sustained remission of Sézary syndrome.
Bouwhuis SA; McEvoy MT; Davis MD
Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
[TBL] [Abstract][Full Text] [Related]
24. Additional courses of total skin electron beam therapy in the treatment of patients with recurrent cutaneous T-cell lymphoma.
Wilson LD; Quiros PA; Kolenik SA; Heald PW; Braverman IM; Edelson RL; Kacinski BM
J Am Acad Dermatol; 1996 Jul; 35(1):69-73. PubMed ID: 8682967
[TBL] [Abstract][Full Text] [Related]
25. On the diagnosis of erythrodermic cutaneous T-cell lymphoma.
Vonderheid EC
J Cutan Pathol; 2006 Feb; 33 Suppl 1():27-42. PubMed ID: 16412210
[TBL] [Abstract][Full Text] [Related]
26. Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma.
Funk A; Hensley F; Krempien R; Neuhof D; Van Kampen M; Treiber M; Roeder F; Timke C; Herfarth K; Helmbold P; Debus J; Bischof M
Eur J Dermatol; 2008; 18(3):308-12. PubMed ID: 18474461
[TBL] [Abstract][Full Text] [Related]
27. Extent of skin involvement as a prognostic indicator of disease free and overall survival of patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy.
Quiros PA; Kacinski BM; Wilson LD
Cancer; 1996 May; 77(9):1912-7. PubMed ID: 8646693
[TBL] [Abstract][Full Text] [Related]
28. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
Rook AH; Gottlieb SL; Wolfe JT; Vowels BR; Sood SS; Niu Z; Lessin SR; Fox FE
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():16-20. PubMed ID: 9020930
[TBL] [Abstract][Full Text] [Related]
29. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sézary syndrome) and benign inflammatory disease: correlation with clinical, histological and immunophenotypical findings.
Ponti R; Quaglino P; Novelli M; Fierro MT; Comessatti A; Peroni A; Bonello L; Bernengo MG
Br J Dermatol; 2005 Sep; 153(3):565-73. PubMed ID: 16120144
[TBL] [Abstract][Full Text] [Related]
30. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
[TBL] [Abstract][Full Text] [Related]
31. Serological immunomarkers in cutaneous T cell lymphoma.
Hassel JC; Meier R; Joller-Jemelka H; Burg G; Dummer R
Dermatology; 2004; 209(4):296-300. PubMed ID: 15539892
[TBL] [Abstract][Full Text] [Related]
32. BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma.
Ohmatsu H; Sugaya M; Miyagaki T; Suga H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Br J Dermatol; 2012 Aug; 167(2):359-67. PubMed ID: 22512719
[TBL] [Abstract][Full Text] [Related]
33. Photopheresis for the treatment of cutaneous T-cell lymphoma.
Lim HW; Edelson RL
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1117-26. PubMed ID: 8522488
[TBL] [Abstract][Full Text] [Related]
34. Review of extracorporeal photopheresis in early-stage (IA, IB, and IIA) cutaneous T-cell lymphoma.
Miller JD; Kirkland EB; Domingo DS; Scull H; Jekutis B; Dallas M; Cooper KD; Baron ED
Photodermatol Photoimmunol Photomed; 2007 Oct; 23(5):163-71. PubMed ID: 17803594
[TBL] [Abstract][Full Text] [Related]
35. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
36. Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases.
Schreiner T; Gaczkowski A; Scharffetter-Kochanek K; Borberg H
Transfus Apher Sci; 2005 Apr; 32(2):197-203. PubMed ID: 15784454
[TBL] [Abstract][Full Text] [Related]
37. Skin-homing CD8+ T lymphocytes show preferential growth in vitro and suppress CD4+ T-cell proliferation in patients with early stages of cutaneous T-cell lymphoma.
Thestrup-Pedersen K; Parhar R; Wu K; Bertilsson PA; Meyer B; Abu-Amero S; Hainau B; Aleisa A; Alfadley A; Hamadah I; Alajlan A; Al-Hussein K; Al-Mohanna F
Acta Derm Venereol; 2007; 87(2):118-26. PubMed ID: 17340017
[TBL] [Abstract][Full Text] [Related]
38. [Clinical and flow cytometry outcome of improved photopheresis methods in dermatologic patients].
Ullrich H; Stolz W; Barlage S; Lackner KJ; Rothe G; Schmitz G
Beitr Infusionsther Transfusionsmed; 1997; 34():256-64. PubMed ID: 9417345
[TBL] [Abstract][Full Text] [Related]
39. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
40. A randomized cross-over study to compare PUVA and extracorporeal photopheresis in the treatment of plaque stage (T2) mycosis fungoides.
Child FJ; Mitchell TJ; Whittaker SJ; Scarisbrick JJ; Seed PT; Russell-Jones R
Clin Exp Dermatol; 2004 May; 29(3):231-6. PubMed ID: 15115499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
